Summary Slide.png (65.62 kB)

Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis

Download (65.62 kB)
figure
posted on 04.09.2018 by Neil M. Schultz, Scott C. Flanders, Samuel Wilson, Bruce A. Brown, Yan Song, Hongbo Yang, Stanislav Lechpammer, Vahan Kassabian

Article full text

The article associated with this content has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on this page in the next few days.

Provide enhanced digital content for this article
If you are an author of this publication and would like to provide additional enhanced digital content for your article then please contact adisrapidplus@springer.com.

The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.

Other enhanced features include, but are not limited to:
• Slide decks
• Videos and animations
• Audio abstracts
• Audio slides

Funding

Astellas Pharma Inc.

History

Exports